TABLE 3.
Comparison of Mp-Associated SJS and Non–Mp-Associated SJS, October 2008–November 2013
| Variable | Mp-SJS (n = 17) | Non–Mp-SJS (n = 23) | OR (CI) | P | All Inpatients (n = 35 964) |
|---|---|---|---|---|---|
| Demographics | |||||
| Age, y, median (IQR) | 12.7 (10.0–14.5) | 11.7 (6.8–15.1) | — | NS | 6.8 ± 6.9 |
| Male, n (%) | 12 (71) | 14 (61) | 1.5 (0.6–2.9) | NS | 19 843 (55) |
| Race, nonwhite, n (%) | 2 (12) | 8 (35) | 0.3 (0.1–1.5) | .097 | 3356 (9) |
| Ethnicity, Hispanic, n (%) | 4 (24) | 6 (26) | 0.9 (0.4–2.2) | NS | 10 077 (28) |
| Clinical | |||||
| Fever (≥39.5°C), n (%) | 16 (94) | 20 (87) | 2.4 (0.3–10.1) | NS | — |
| Oral involvement, n (%) | 17 (100) | 23 (100) | N/A | N/A | — |
| Conjunctival involvement, n (%) | 16 (94) | 20 (87) | 2.4 (0.3–10.1) | NS | — |
| Genital involvement, n (%) | 14 (82) | 17 (74) | 1.6 (0.5–3.7) | NS | — |
| No. mucus membranes involved, median (IQR) | 3 (3–3) | 3 (2.5–3) | — | NS | — |
| ≥3 mucus membranes involved, n (%) | 13 (76) | 17 (74) | 1.1 (0.3–4.9) | NS | — |
| Skin involvement, n (%) | 13 (76) | 21 (91) | 0.3 (0.3–1.2) | NS | — |
| No. of skin sites involved, median (IQR) | 1 (1–4) | 4 (2.5–4) | — | .047 | — |
| ≤3 skin sites involved, n (%) | 12 (71) | 8 (35) | 4.5 (1.2–17.4) | — | |
| Recurrent SJS, n (%) | 4 (24) | 3 (13) | 2.1 (0.7–3.1) | NS | — |
| Pneumonia, n (%) | 9 (53) | 3 (13) | 10.0 (1.3–5.1) | .002 | — |
| Preceding antibiotics or AEDs,a n (%) | 0 (0) | 9 (39) | 1/infinity | <.001 | — |
| Preceding URI symptoms, n (%) | 16 (94) | 8 (35) | 30 (1.6–72.6) | <.001 | — |
| Household contacts with URI,b n (%) | 5 (50) | 4 (31) | 2.0 (0.6–3.9) | NS | — |
| ESR >35 mg/dL, n (%)c | 7 (64) | 1 (7) | 22.8 (2.1–244.9) | — | |
| Max CRP mg/dL, median (IQR)d | 7.5 (2.9–10.5) | 6.3 (2.8–11.8) | — | NS | — |
| Treatment | |||||
| Days hospitalized, median (IQR) | 9 (5–12) | 11 (5–12.5) | — | NS | — |
| NG feeding or TPN days, median (IQR) | 7 (0–9) | 5 (0–10) | — | NS | — |
| PCA/continuous opioid, d, median (IQR) | 0 (0–9) | 0 (0–9) | — | NS | — |
| ICU admission, n (%) | 5 (29) | 5 (22) | 1.5 (0.6–2.7) | NS | — |
| Amniotic graft, n (%) | 6 (35) | 7 (32) | 1.2 (0.5–2.4) | NS | — |
AED, antiepileptic drug; CRP, C-reactive protein; N/A, not applicable; NG, nasogastric; NS, nonsignificant; PCA, patient-controlled analgesia; TPN, total parenteral nutrition; URI, upper respiratory infection; —, not recorded.
a
Did not include azithromycin as a preceding antibiotic.
b
Seven cases and 10 controls with missing data.
c
Six cases and 9 controls with missing data.
d
Four cases and 4 controls with missing data.